<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1224">
  <stage>Registered</stage>
  <submitdate>7/07/2006</submitdate>
  <approvaldate>7/07/2006</approvaldate>
  <nctid>NCT00349791</nctid>
  <trial_identification>
    <studytitle>Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido</studytitle>
    <scientifictitle>A Study to Evaluate the Efficacy/Safety of Transdermal Testosterone for 24 Weeks in Naturally Menopausal Women With Hypoactive Sexual Desire Disorder on Oral Hormone Replacement Therapy.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2002006</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypoactive Sexual Desire Disorder (HSDD)</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Testosterone Transdermal System
Treatment: drugs - Placebo patch

Placebo Comparator: 1 - placebo patch replaced twice a week for two years

Experimental: 2 - testosterone patch replaced twice a week for two years


Treatment: drugs: Testosterone Transdermal System
testosterone (300 mcg/day) patch replaced twice a week for two years

Treatment: drugs: Placebo patch
placebo patch replaced twice a week for two years

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the efficacy of the transdermal system (TTS) as measured by the change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL).</outcome>
      <timepoint>2 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the efficacy measured by the change from baseline in sexual desire using personal distress as measured by the Personal Distress Scale (PDS) score; the other 6 domains of the Profile of Female Sexual function, and the other 8 SAL endpoints.</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Eligible women must:

          1. Be 40-70 years old and in generally good health

          2. Be post-menopausal with no spontaneous periods for 1 year

          3. Be receiving a stable dose of hormone replacement therapy for at least 3 months pror
             to screening with the intention of maintaining that regimen.

          4. Be, in her own judgment, in a stable, monogamous sexual relationship that is perceived
             to be secure and communicative, for at least one year prior to study entry

          5. Meet the criteria for having hypoactive sexual desire disorder</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Eligible women must not:

          1. Have received androgen therapy at any time during the past 3 months (during the past 7
             months if therapy was an investigational implantable product)

          2. Be experiencing any chronic or acute life stress relating to any major life change

          3. Be experiencing depression and/or receiving medication for such illness or disorder

          4. Have current severe skin problems (such as severe or cystic acne) or allergy to
             adhesives (like the ones in bandages)

          5. Have had a major illness, active gall bladder disease, or gynecological or breast
             surgery within the last 6 months

          6. Have a history of breast, endometrial, or other gynecological cancer at any time
             before study participation or other cancer within the last 5 years

          7. Have diabetes, a history of cerebrovascular disease, thrombo-embolic disorders, heart
             attack, or angina at any time before study participation or thrombophlebitis within
             the last 5 years

          8. Have abnormal laboratory test results upon initial screening for this study

          9. Have previously participated in a clinical trial within 30 days or received an
             investigational medication within 30 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>549</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2003</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Facility - Randwick</hospital>
    <postcode> - Randwick</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Warner Chilcott</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to evaluate efficacy and safety of a testosterone patch as treatment
      for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin
      therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00349791</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Johna Lucas, MD</name>
      <address>Procter and Gamble</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>